Research into better cancer treatments has been a progressively growing field. Metal containing coordination compounds offer unique chemistry that could prove useful. A ruthenium(III) compound with two indazole and four chlorine ligands, KP1019, is currently in phase III clinical trials as a pro-drug for the treatment of cancer. Our research delved into creating similar compounds to KP1019 but with cobalt centers instead of ruthenium, and with...